Table 1.
Baseline demographics and disease characteristics
| Parameter | Arm A azacitidine + durvalumab n = 64 | Arm B azacitidine n = 65 |
|---|---|---|
| Median age (range), y | 76.0 (65-89) | 75.0 (65-87) |
| Sex, M/F, n | 40/24 | 31/34 |
| ECOG status 0/1/2, % | 29.7/62.5/7.8 | 40.0/49.2/10.8 |
| Median hemoglobin, g/L | 88.5 | 93.0 |
| Median transfusion burden, units/28 d | 2.00 | 2.00 |
| Median platelet count, ×109/L | 55.5 | 42.0 |
| Low platelets (<100 000), % | 0 | 0 |
| Median ANC, ×109/L | 0.595 | 0.430 |
| Low ANC (<100), % | ||
| Band form | 0 | 0 |
| Segmented | 58 (91) | 55 (92) |
| Median time since diagnosis, months | 1.00 | 0.80 |
| Secondary AML, % | ||
| Yes | 42.2 | 41.5 |
| No | 56.3 | 56.9 |
| Cytogenetic risk category per NCCN guidelines, % | ||
| Intermediate | 39.1 | 40.0 |
| Poor | 25.0 | 24.6 |
| Missing | 35.9 | 35.4 |
| Median BM blasts, % | 34.00 | 32.00 |
| BM blast % category, %* | ||
| <20 | 3.1 | 6.2 |
| 20 to <30 | 37.5 | 35.4 |
| ≥30 | 57.8 | 58.5 |
| Main WHO classes, % | ||
| AML with MDS-related changes | 39.1 | 58.5 |
| AML not otherwise specified | 39.1 | 27.7 |
| TP53 mutation status, %† | ||
| WT | 67 | 74 |
| Mutated | 33 | 26 |
ANC, absolute neutrophil count; ECOG, Eastern Cooperative Oncology Group; F, female; IPSS-R, Revised International Prognostic Scoring System; M, male; WHO, World Health Organization.
*
Missing category not displayed.
†
n = 105.